Journal
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 26, Issue 6, Pages 778-783Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0269881111413821
Keywords
Posttraumatic stress disorder; remission; resilience; venlafaxine extended release
Funding
- Wyeth Research, Collegeville, Pennsylvania
- Wyeth
- Dennis Stancavish, MA, of Embryon, LLC, A Division of Advanced Health Media, LLC
- Astrazeneca
- Eli-Lilly
- GlaxoSmithKline
- Jazz Pharmaceuticals
- Johnson Johnson
- Lundbeck
- Orion
- Pfizer
- Pharmacia
- Roche
- Servier
- Solvay
- Sumitomo
- Takeda
- Tikvah
Ask authors/readers for more resources
This post-hoc analysis evaluated resilience as a predictor of treatment response in patients with posttraumatic stress disorder (PTSD). Data were pooled from two randomized, double-blind studies conducted with adult outpatients treated with flexible doses of venlafaxine extended release (ER) 37.5 to 300 mg/day or placebo. The 17-item Clinician-Administered Posttraumatic Stress Disorder Scale (CAPS-SX17) was the primary outcome measure. Baseline Connor-Davidson Resilience Scale (CD-RISC) scores for the 25-, 10-, and 2-item versions were used to predict changes in PTSD symptom severity at week 12 and symptomatic remission (CAPS-SX17 <= 20). Analyses were conducted for the overall population and separately for the individual treatment groups. In total, pretreatment resilience predicted a positive treatment response. For the overall population, all versions of the CD-RISC predicted CAPS-SX17 change scores and remission after controlling for variables such as treatment group and baseline symptom severity. For venlafaxine ER-treated patients, all versions of the CD-RISC were predictive of remission, but only the 10-item version was predictive of CAPS-SX17 change score. Our results suggest that higher pretreatment resilience is generally associated with a positive treatment response. Future research may be warranted to explore the relationship between response to active treatment and the spectrum of resiliency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available